Unidirectional crosstalk between Bcl-xL and Bcl-2 enhances the angiogenic phenotype of endothelial cells

Cell Death and Differentiation

Volumn 14, Issue 9, 2007, Pages 1657-1666

  Karl, E ^a   Zhang, Z ^a   Dong, Z ^a   Neiva, K G ^a   Soengas, M S ^b   Koch, A E ^b   Polverini, P J ^a   Nunez G ^b,c   Nor J E ^a,c  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN BCL XL; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DOWNSTREAM PROCESSING; ENDOTHELIUM CELL; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKIN EPITHELIUM; UPREGULATION;

ANIMALS; APOPTOSIS; BCL-X PROTEIN; CHEMOKINE CXCL1; ENDOTHELIAL CELLS; EPIDERMAL GROWTH FACTOR; HUMANS; INTERLEUKIN-8; MICE; MICE, SCID; NEOVASCULARIZATION, PHYSIOLOGIC; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSDUCTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548028728     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4402174     Document Type: Article

References (35)

1. Reinmuth N, Stoeltzing O, Liu W, Ahmad SA, Jung YD, Fan F et al. Endothelial survival factors as targets for anti-neoplastic therapy. Cancer J 2001; 7: S109-S119.
2. Nör JE, Polverini PJ. Role of endothelial cell survival and death signals in angiogenesis. Angiogenesis 1999; 3: 101-116.
3. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 10: 1024-1028.
4. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/ Akt signal transduction pathway. Requirement for Fik-1/KDR activation. J Biol Chem 1998; 46: 30336-30343.
5. Nör JE, Christensen J, Mooney, DJ, Polverini PJ. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced andothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999; 154: 375-384.
6. Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998; 18: 10820-10825.
7. Nör JE, Mitra RS, Sutorik MM, Mooney DJ, Castle VP, Polverini PJ. Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res 2000; 37: 142-150.
8. Zeitlin BD, Joo E, Dong Z, Warner K, Wang G, Nikolovska-Coleska Z et al. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res 2006; 66: 8698-8706.
9. Nör JE, Peters MC, Christensen JB, Sutorik MM, Linn S, Khan MK et al. Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 2001; 61: 2183-2188.
10. Karl E, Warner K, Zeitlin B, Kaneko T, Wurtzel L, Jin T Chang J et al. Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. Cancer Res 2005; 65: 5063-5069.
11. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
12. Chao DT, Linette GP, Boise LH, White LS, Thompson CB, Korsmeyer SJ. Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med 1995, 3: 821-828.
13. Chao DT, Korsmeyer SJ. BCL-2 family: Regulators of cell death. Annu Rev Immunol 1998; 16: 395-419.
14. Kedar D, Baker CH, Killion JJ, Dinney CP, Fidler IJ. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 2002; 8: 3592-3600.
15. Cui XS, Kim NH. Epidermal growth factor induces Bcl-xL gene expression and reduces apoptosis in porcine parthenotes developing in vitro. Mol Reprod Dev 2003; 66 273-278.
16. Minn AJ, Kettlun CS, Liang H, Kelekar A, Vander Heiden MG, Chang BS et al. Bcl-xL regulates apoptosis by heterodimerization-dependent and -independent mechanisms. EMBO J 1999; 18: 632-643.
17. Baggiolini M, Dewald B, Moser B. Interleukin-B and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 1994; 55: 97-179.
18. Bemardini G, Ribatti D, Spinetti G, Morbidelli L, Ziche M, Santoni A et al. Analysis of the role of chemokines in angiogenesis. J Immunol Methods 2003; 273: 83-101.
19. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J et al. PTK787/ZK222584, a novel and patent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-2189.
20. de Moissac D, Mustapha S, Greenberg AH, Kirshenbaum LA. Bcl-2 activates the transcription factor NFkappaB through the degradation of the cytoplasmic inhibitor lkappaBalpha. J Biol Chem 1998; 273: 23946-23951.
21. Ricca A, Biroccio A, Del Bufalo D, Mackay AR, Santoni A, Cippitelli M. bcl-2 overexpression enhances NF-kappaB activity and induces mmp-9 transcription in human MCF7 (ADR) breast-cancer cells. Int J Cancer 2000; 86: 188-196.
22. Distler JH, Hagen C, Hirth A, Muller-Ladner U, Lorenz HM, del Rosso A et al. Bucillamine induces the synthesis of vascular endothelial growth fractor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-kappaB and simian virus 40 promoter factor 1 pathways. Mol Pharmacol 2004; 2: 389-399.
23. Nör JE, Peters MC, Christensen JB, Sutorik MM, Linn S, Khan MK et al. Engineering and characterization of functional human microvessels in immunodeficient mice. Lab Invest 2001; 81: 453-463.
24. Strieter RM, Polverini PJ, Arenberg DA, Kunkel SL. The role of CXC chamokines as regulators of angiogenesis. Shock 1995; 3: 155-160.
25. Amin DN, Hida K, Bielenberg DR, Klagsbrun M. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 2006; 66: 2173-2180.
26. Knipling L, Wolff J. Direct interaction of Bcl-2 proteins with tubulin. Biochem Biophys Res Commun 2006; 2: 433-439.
27. Zachary I, Gliki G. Signaling transduction mechanism mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 3: 568-581.
28. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006, 5: 549-560.
29. Sun C, Hu Y, Liu X, Wu T, Wang Y, He W et al. Resveratrol 'downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet Cytogenet 2006; 1: 9-19.
30. Jazirehi AR, Vega MI, Chattejee D, Goodglick L, Bonavida B. Inhibition of the Raf-MEK1/ 2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res 2004; 19: 7117-7126.
31. Coles LS, Lambrusco L, Burrows J, Hunter J, Diamond P, Bert AG et al. Phosphorylation of cold shock domain/Y-box proteins by ERK2 and GSK3beta and repression of the human VEGF promoter. FEBS Lett 2005; 579: 5372-5378.
32. Kawano Y, Nakamura S, Fukuda J, Sugano J, Takai N, Miyakawa I. The effect of epidermal growth factor on production of vascular endothelial growth factor by amnion-derived (WISH) cells. Growth Factors 2005; 2: 169-175.
33. Verhaegan M, Bauer JA, Martin de la Vega C, Wang G, Wolter KG, Brenner JC et al. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 2006; 66: 11348-11359.
34. Cioca DP, Aoki Y, Kiyosawa K. RNA Interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther 2003; 10: 125-133.
35. Jiang M, Milner J. Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev 2003; 17: 832-837.